Avandia (rosiglitazone): REMS – Risk of Cardiovascular Events
Audience: Endocrinology, Cardiology [Posted 09/23/2010]
ISSUE: FDA notified healthcare professionals and patients that it will significantly restrict the use of the diabetes drug Avandia (rosiglitazone) to patients with Type 2 diabetes who cannot…
No related posts.




facebook
rss
twitter